Patents by Inventor Mark Trautwein
Mark Trautwein has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20240124572Abstract: The present invention is related to agents capable of binding to and inhibiting or antagonizing the action of IL-11 and/or or IL-11RA for the treatment and/or prevention of abnormal uterine bleeding, which comprises heavy menstrual bleeding, prolonged bleeding, altered bleeding pattern, dysmenorrhea, as well as of the underlying diseases leiomyoma and endometriosis and the use of the agent to inhibit menstruation. Furthermore, the invention provides novel IL-11 antibodies.Type: ApplicationFiled: February 24, 2022Publication date: April 18, 2024Inventors: Maik Stefan Wilhelm OBENDORF, Frank SACHER, Jörg MÜLLER, Ralf LESCHE, Christian VOTSMEIER, Stephan MÄRSCH, Jan TEBBE, Philipp ELLINGER, Patrick Michael SMITH, Jenny FITTING, Katharina FILARSKY, Mathias GEHRMANN, Marcus KARLSTETTER, Ernst WEBER, Mark TRAUTWEIN
-
Publication number: 20240108766Abstract: The present invention relates to conjugates comprising a chelator arranged for complexation of a radionuclide and a targeting moiety binding to LRRC15. For example, the conjugates according to the current invention can be targeted alpha therapeutics such as targeted thorium conjugates (TTCs), i.e. radioconjugates comprising an alpha emitter, such as 227Th. The present invention further relates to sequence-defined antibodies binding LRRC15 and antigen-binding fragments thereof. Also provided are conjugates comprising these antibodies or functional fragments thereof. The antibodies, functional fragments and conjugates according to the current invention can be used to treat cancer and other disorders and conditions associated with the expression of LRRC15.Type: ApplicationFiled: January 17, 2022Publication date: April 4, 2024Inventors: Mark TRAUTWEIN, Urs Beat HAGEMANN, Phillipp ELLINGER, Stephan MAERSCH, Joachim SCHUHMACHER, Antje WENGNER, Roger Malerbakken BJERKE, Helge ROIDER
-
Patent number: 11866495Abstract: The present invention provides recombinant antigen-binding regions and antibodies and functional fragments containing such antigen-binding regions that are specific for human and Macaca fascicularis CEACAM6 (Carcinoembryonic antigen-related cell adhesion molecule 6, CD66c, Non-specific crossreacting antigen, NCA, NCA-50/90), and which do not significantly cross-react with the closely related human CEACAM1, human CEACAM3, and human CEACAM5. The invention further provides methods to generate this kind of antibodies. The antibodies, accordingly, can be used to treat cancer and other disorders and conditions associated with expression of the CEACAM6. The invention also provides nucleic acid sequences encoding the foregoing antibodies, vectors containing the same, pharmaceutical compositions and kits with instructions for use.Type: GrantFiled: January 29, 2020Date of Patent: January 9, 2024Assignee: Deutsches Krebsforschungszentrum Stiftung des öffentlichen RechtsInventors: Jörg Willuda, Mark Trautwein, Uwe Gritzan, Christoph Freiberg, Frank Dittmer, Dorian Schönfeld, Julian Marius Glück, Jessica Pinkert, Eva-Maria Gutierrez, Sven Golfier, Simon Holton, Philip Beckhove, Yingzi Ge
-
Patent number: 11773164Abstract: The present invention provides recombinant antigen-binding regions and antibodies and functional fragments containing such antigen-binding regions that are specific for human and Macaca fascicularis CEACAM6 (Carcinoembryonic antigen-related cell adhesion molecule 6, CD66c, Non-specific crossreacting antigen, NCA, NCA-50/90), and which do not significantly cross-react with the closely related human CEACAM1, human CEACAM3, and human CEACAM5. The invention further provides methods to generate this kind of antibodies. The antibodies, accordingly, can be used to treat cancer and other disorders and conditions associated with expression of the CEACAM6. The invention also provides nucleic acid sequences encoding the foregoing antibodies, vectors containing the same, pharmaceutical compositions and kits with instructions for use.Type: GrantFiled: January 29, 2020Date of Patent: October 3, 2023Assignee: Deutsches Krebsforschungszentrum Stiftung des öffentlichen RechtsInventors: Jörg Willuda, Mark Trautwein, Uwe Gritzan, Christoph Freiberg, Frank Dittmer, Dorian Schönfeld, Julian Glück, Jessica Pinkert, Eva-Maria Gutierrez, Sven Golfier, Simon Holton, Philip Beckhove, Yingzi Ge
-
Publication number: 20230250178Abstract: The present invention relates to tools and methods for the generation of antibodies which specifically bind chemokine receptors, such as CC or CXC chemokine receptors. Provided are isolated sulfated polypeptides and conjugates thereof, which can be used for example as antigens or for off target panning to facilitate the generation of anti-human, anti-cynomolgus, and/or anti-mouse chemokine receptor antibodies, e.g. for the generation of antibodies with fully human CDRs and/or other favorable properties for therapeutic use. The present invention furthermore relates to antibodies and conjugates thereof which can be obtained by applying the aforementioned tools and methods. Provided are antibodies specifically binding to human, cynomolgus and/or murine CCR8 with favorable properties for therapeutic use, such as cross-reactive antibodies, fully human antibodies, low internalizing (including non-internalizing) antibodies, and antibodies efficiently inducing ADCC and/or ADCP in Treg cells.Type: ApplicationFiled: June 25, 2021Publication date: August 10, 2023Inventors: Sandra BERNDT, Katharina FILARSKY, Philipp ELLINGER, Beatrix STELTE-LUDWIG, Sabine HOFF, Helge ROIDER, Ernst WEBER, Mark TRAUTWEIN, Christian VOTSMEIER, Nikolaus PAWLOWSKI, Uwe GRITZAN, Pascale BUCHMANN, Christian BERTLING, Oliver VON AHSEN, Wiebke Maria NADLER, Su-Yi TSENG, Pedro PAZ, Phaik Lyn OH, Patrick JONES, Matyas GORJANACZ
-
Publication number: 20220089721Abstract: The present disclosure relates to combinations of at least two components, component A and component B, component A being anti-CEACAM6 antibody TPP-3310 and component B being an anti-TIM-3 antibody, preferentially cobolimab, MBG-453, BMS-986258, Sym-023, LY-3321367 or INCAGN-2390.Type: ApplicationFiled: December 12, 2019Publication date: March 24, 2022Applicants: Bayer Aktiengesellschaft, Deutsches KrebsforschungszentrumInventors: Jrög WILLUDA, Mark TRAUTWEIN, Rienk OFFRINGA, Hans-Henning BÖHM, Philipp BECKHOVE
-
Publication number: 20220010017Abstract: Pharmaceutical Combination for the Treatment of Cancer The present invention relates to combinations of at least two components, component A and component B for use in the treatment of cancer, component A being an anti-CEACAM6 antibody and component B being an anti-PD-1 antibody, preferentially nivolumab, or pembrolizumab, or an anti-PD-L1 antibody, preferentially atezolizumab, avelumab, or durvalumab.Type: ApplicationFiled: November 7, 2019Publication date: January 13, 2022Applicants: Bayer Aktiengesellschaft, Deutsches KrebsforschungszentrumInventors: Jörg WILLUDA, Mark TRAUTWEIN, Rienk OFFRINGA, Philipp BECKHOVE, Hans-Henning BÖHM
-
Patent number: 11071788Abstract: The present application relates to novel binder drug conjugates (ADCs), to active metabolites of these ADCs, to processes for preparing these ADCs, to the use of these ADCs for the treatment and/or prophylaxis of diseases and to the use of these ADCs for preparing medicaments for treatment and/or prophylaxis of diseases, in particular hyperproliferative and/or angiogenic disorders such as, for example, cancer diseases. Such treatments can be effected as monotherapy or else in combination with other medicaments or further therapeutic measures.Type: GrantFiled: June 20, 2016Date of Patent: July 27, 2021Assignee: BAYER PHARMA AKTIENGESELLSCHAFTInventors: Hans-Georg Lerchen, Anne-Sophie Rebstock, Yolanda Cancho Grande, Sven Wittrock, Sandra Berndt, Uwe Gritzan, Jenny Fitting, Beatrix Stelte-Ludwig, Patrick Jones, Christoph Mahlert, Christian Votsmeier, Dorian Schönfeld, Mark Trautwein, Ernst Weber, Nikolaus Pawlowski, Simone Greven, Julian Marius Glück, Stefanie Hammer, Lisa Dietz, Stephan Märsch
-
Publication number: 20200181261Abstract: The present invention provides recombinant antigen-binding regions and antibodies and functional fragments containing such antigen-binding regions that are specific for human and Macaca fascicularis CEACAM6 (Carcinoembryonic antigen-related cell adhesion molecule 6, CD66c, Non-specific crossreacting antigen, NCA, NCA-50/90), and which do not significantly cross-react with the closely related human CEACAM1, human CEACAM3, and human CEACAM5. The invention further provides methods to generate this kind of antibodies. The antibodies, accordingly, can be used to treat cancer and other disorders and conditions associated with expression of the CEACAM6. The invention also provides nucleic acid sequences encoding the foregoing antibodies, vectors containing the same, pharmaceutical compositions and kits with instructions for use.Type: ApplicationFiled: January 29, 2020Publication date: June 11, 2020Applicant: Bayer Pharma AktiengesellschaftInventors: Jörg WILLUDA, Mark TRAUTWEIN, Uwe GRITZAN, Christoph FREIBERG, Frank DITTMER, Dorian SCHÖNFELD, Julian Marius GLÜCK, Jessica PINKERT, Eva-Maria GUTIERREZ, Sven GOLFIER, Simon HOLTON, Philip BECKHOVE, Yingzi GE
-
Publication number: 20200157214Abstract: The present invention provides recombinant antigen-binding regions and antibodies and functional fragments containing such antigen-binding regions that are specific for human and Macaca fascicularis CEACAM6 (Carcinoembryonic antigen-related cell adhesion molecule 6, CD66c, Non-specific crossreacting antigen, NCA, NCA-50/90), and which do not significantly cross-react with the closely related human CEACAM1, human CEACAM3, and human CEACAM5. The invention further provides methods to generate this kind of antibodies. The antibodies, accordingly, can be used to treat cancer and other disorders and conditions associated with expression of the CEACAM6. The invention also provides nucleic acid sequences encoding the foregoing antibodies, vectors containing the same, pharmaceutical compositions and kits with instructions for use.Type: ApplicationFiled: January 29, 2020Publication date: May 21, 2020Applicant: Bayer Pharma AktiengesellschaftInventors: Jörg WILLUDA, Mark TRAUTWEIN, Uwe GRITZAN, Christoph FREIBERG, Frank DITTMER, Dorian SCHÖNFELD, Julian Marius GLÜCK, Jessica PINKERT, Eva-Maria GUTIERREZ, Sven GOLFIER, Simon HOLTON, Philip BECKHOVE, Yingzi GE
-
Publication number: 20200138970Abstract: The present application relates to novel binder drug conjugates (ADCs), to active metabolites of these ADCs, to processes for preparing these ADCs, to the use of these ADCs for the treatment and/or prophylaxis of diseases and to the use of these ADCs for preparing medicaments for treatment and/or prophylaxis of diseases, in particular hyperproliferative and/or angiogenic disorders such as, for example, cancer diseases. Such treatments can be effected as monotherapy or else in combination with other medicaments or further therapeutic measures.Type: ApplicationFiled: June 20, 2016Publication date: May 7, 2020Inventors: Hans-Georg LERCHEN, Anne-Sophie REBSTOCK, Yolanda CANCHO GRANDE, Sven WITTROCK, Sandra BERNDT, Uwe GRITZAN, Jenny FITTING, Beatrix STELTE-LUDWIG, Patrick JONES, Christoph MAHLERT, Christian VOTSMEIER, Dorian SCHÖNFELD, Mark TRAUTWEIN, Ernst WEBER, Nikolaus PAWLOWSKI, Simone GREVEN, Julian Marius GLÜCK, Stefanie HAMMER, Lisa DIETZ, Stephan MÄRSCH
-
Patent number: 10584167Abstract: The present invention provides recombinant antigen-binding regions and antibodies and functional fragments containing such antigen-binding regions that are specific for human and Macaca fascicularis CEACAM6 (Carcinoembryonic antigen-related cell adhesion molecule 6, CD66c, Non-specific crossreacting antigen, NCA, NCA-50/90), and which do not significantly cross-react with the closely related human CEACAM1, human CEACAM3, and human CEACAM5. The invention further provides methods to generate this kind of antibodies. The antibodies, accordingly, can be used to treat cancer and other disorders and conditions associated with expression of the CEACAM6. The invention also provides nucleic acid sequences encoding the foregoing antibodies, vectors containing the same, pharmaceutical compositions and kits with instructions for use.Type: GrantFiled: March 21, 2016Date of Patent: March 10, 2020Assignee: Bayer Pharma AktiengesellschaftInventors: Jörg Willuda, Mark Trautwein, Uwe Gritzan, Christoph Freiberg, Frank Dittmer, Dorian Schönfeld, Julian Marius Glück, Jessica Pinkert, Eva-Maria Gutierrez, Sven Golfier, Simon Holton, Philip Beckhove, Yingzi Ge
-
Publication number: 20190298865Abstract: The invention provides a method for the formation of a tissue-targeting thorium complex, said method comprising; a) forming an octadentate chelator comprising four hydroxypyridinone (HOPO) moieties, substituted in the N-position with a methyl group, and a coupling moiety terminating in a carboxylic acid group; b) coupling said octadentate chelator to at least one tissue-targeting moiety targeting prolyl endopeptidase FAP; and c) contacting said tissue-targeting chelator with an aqueous solution comprising an ion of at least one alpha-emitting thorium isotope. A method of treatment of a neoplastic or hyperplastic disease comprising administration of such a tissue-targeting thorium complex, as well as the complex and corresponding pharmaceutical formulations are also provided.Type: ApplicationFiled: June 6, 2017Publication date: October 3, 2019Applicants: BAYER PHARMA AKTIENGESELLSCHAFT, BAYER ASInventors: Alan CUTHBERTSON, Mark TRAUTWEIN, Ernst WEBER, Jenny KARLSSON, Stefanie HAMMER
-
Publication number: 20180162940Abstract: The present invention provides recombinant antigen-binding regions and antibodies and functional fragments containing such antigen-binding regions that are specific for human and Macaca fascicularis CEACAM6 (Carcinoembryonic antigen-related cell adhesion molecule 6, CD66c, Non-specific crossreacting antigen, NCA, NCA-50/90), and which do not significantly cross-react with the closely related human CEACAM1, human CEACAM3, and human CEACAM5. The invention further provides methods to generate this kind of antibodies. The antibodies, accordingly, can be used to treat cancer and other disorders and conditions associated with expression of the CEACAM6. The invention also provides nucleic acid sequences encoding the foregoing antibodies, vectors containing the same, pharmaceutical compositions and kits with instructions for use.Type: ApplicationFiled: March 21, 2016Publication date: June 14, 2018Applicant: Bayer Pharma AktiengesellschaftInventors: Jörg WILLUDA, Mark TRAUTWEIN, Uwe GRITZAN, Christoph FREIBERG, Frank DITTMER, Dorian SCHÖNFELD, Julian Marius GLÜCK, Jessica PINKERT, Eva-Maria GUTIERREZ, Sven GOLFIER, Simon HOLTON, Philip BECKHOVE, Yingzi GE
-
Patent number: 9777063Abstract: The present invention is directed to the neutralizing prolactin receptor antibody Mat3, and antigen binding fragments, pharmaceutical compositions containing them and their use in the treatment or prevention of benign disorders and indications mediated by the prolactin receptor such as endometriosis, adenomyosis, non-hormonal female contraception, benign breast disease and mastalgia, lactation inhibition, benign prostate hyperplasia, fibroids, hyper- and normoprolactinemic hair loss, and cotreatment in combined hormone therapy to inhibit mammary epithelial cell proliferation and for the treatment and prevention of antiestrogen-resistant breast cancer. The antibody of the invention blocks prolactin receptor-mediated signalling.Type: GrantFiled: April 28, 2016Date of Patent: October 3, 2017Assignee: Bayer Intellectual Property GmbHInventors: Christoph Freiberg, Christiane Otto, Lars Linden, Axel Harrenga, Mark Trautwein, Simone Greven, Andreas Wilmen
-
Patent number: 9649374Abstract: The present invention is directed to the neutralizing prolactin receptor antibody 006-H08, as well as maturated forms thereof, and antigen-binding fragments, pharmaceutical compositions containing them and their use in the treatment or prevention of benign disorders and indications mediated by the prolactin receptor such as endometriosis, adenomyosis, non-hormonal female contraception, benign breast disease and mastalgia, lactation inhibition, benign prostate hyperplasia, fibroids, hyper- and normoprolactinemic hair loss, and cotreatment in combined hormone therapy to inhibit mammary epithelial cell proliferation. The antibodies of the invention block prolactin receptor-mediated signaling.Type: GrantFiled: November 18, 2010Date of Patent: May 16, 2017Assignee: Bayer Intellectual Property GMBHInventors: Christiane Otto, Siegmund Wolf, Christoph Freiberg, Axel Harrenga, Simone Greven, Mark Trautwein, Sandra Bruder, Andrea Eicker, Andreas Wilmen
-
Publication number: 20160319029Abstract: The present invention is directed to the neutralizing prolactin receptor antibody Mat3, and antigen binding fragments, pharmaceutical compositions containing them and their use in the treatment or prevention of benign disorders and indications mediated by the prolactin receptor such as endometriosis, adenomyosis, non-hormonal female contraception, benign breast disease and mastalgia, lactation inhibition, benign prostate hyperplasia, fibroids, hyper- and normoprolactinemic hair loss, and cotreatment in combined hormone therapy to inhibit mammary epithelial cell proliferation and for the treatment and prevention of antiestrogen-resistant breast cancer. The antibody of the invention blocks prolactin receptor-mediated signalling.Type: ApplicationFiled: April 28, 2016Publication date: November 3, 2016Inventors: Christoph FREIBERG, Christiane OTTO, Lars LINDEN, Axel HARRENGA, Mark TRAUTWEIN, Simone GREVEN, Andreas WILMEN
-
Patent number: 9382305Abstract: The present invention provides Relaxin fusion polypeptides A-L-B with a non-wild type array of the Relaxin A-chain and Relaxin B-chain, wherein the A- and B-chains are connected by a linker peptide. The invention further provides Relaxin fusion polypeptides with extended half-life. Furthermore, the invention provides nucleic acid sequences encoding the foregoing fusion polypeptides, vectors containing the same, pharmaceutical compositions and medical use of such fusion polypeptides.Type: GrantFiled: June 29, 2012Date of Patent: July 5, 2016Assignee: BAYER INTELLECTUAL PROPERTY GMBHInventors: Andreas Wilmen, Ulrich Haupts, Christoph Freiberg, Mark Trautwein, Lars Linden, Kirsten Leineweber, Hanna Tinel
-
Patent number: 9353186Abstract: The neutralizing prolactin receptor antibody Mat3, and antigen binding fragments, pharmaceutical compositions containing them and their use in the treatment or prevention of benign disorders and indications mediated by the prolactin receptor such as endometriosis, adenomyosis, non-hormonal female contraception, benign breast disease and mastalgia, lactation inhibition, benign prostate hyperplasia, fibroids, hyper- and normoprolactinemic hair loss, and cotreatment in combined hormone therapy to inhibit mammary epithelial cell proliferation and for the treatment and prevention of antiestrogen-resistant breast cancer. The antibody blocks prolactin receptor-mediated signalling.Type: GrantFiled: May 31, 2012Date of Patent: May 31, 2016Assignee: BAYER INTELLECTUAL PROPERTY GMBHInventors: Christoph Freiberg, Christiane Otto, Lars Linden, Axel Harrenga, Mark Trautwein, Simone Greven, Andreas Wilmen
-
Patent number: 9241989Abstract: The present invention is directed to the neutralizing prolactin receptor antibody 005-C04, as well as maturated forms thereof, and antigen binding fragments, pharmaceutical compositions containing them and their use in the treatment or prevention of benign disorders and indications mediated by the prolactin receptor such as endometriosis, adenomyosis, non-hormonal female contraception, benign breast disease and mastalgia, lactation inhibition, benign prostate hyperplasia, fibroids, hyper- and normoprolactinemic hair loss, and cotreatment in combined hormone therapy to inhibit mammary epithelial cell proliferation. The antibodies of the invention block prolactin receptor-mediated signaling.Type: GrantFiled: November 18, 2010Date of Patent: January 26, 2016Assignee: BAYER INTELLECTUAL PROPERTY GMBHInventors: Christiane Otto, Siegmund Wolf, Christoph Freiberg, Axel Harrenga, Simone Greven, Mark Trautwein, Sandra Bruder, Andrea Eicker, Andreas Wilmen